Cargando…

Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes

Detalles Bibliográficos
Autores principales:	Gill, Dipender, Burgess, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676614/ https://www.ncbi.nlm.nih.gov/pubmed/33079601 http://dx.doi.org/10.1161/CIRCGEN.120.003061

Ejemplares similares

Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors
por: Huang, Changjiang, et al.
Publicado: (2017)

Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor?
por: Dutt, Tina, et al.
Publicado: (2020)

Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020)

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking
por: Pu, Yinglan, et al.
Publicado: (2017)

Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity
por: Narita, Yuki, et al.
Publicado: (2019)

Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation
por: Wang, Wenzhi, et al.
Publicado: (2016)

Novel FXa Inhibitor Identification through Integration of Ligand- and Structure-Based Approaches
por: Lagos, Carlos F., et al.
Publicado: (2017)

Characteristics of FXa-storing platelets in hemophilia B mice and the influence of alcohol on the platelets
por: Han, Wenwen, et al.
Publicado: (2023)

Novel Isosteviol-Based FXa Inhibitors: Molecular Modeling, In Silico Design and Docking Simulation
por: Gackowski, Marcin, et al.
Publicado: (2023)

Quantitative Structure–Activity Relationship Analysis of Isosteviol-Related Compounds as Activated Coagulation Factor X (FXa) Inhibitors
por: Gackowski, Marcin, et al.
Publicado: (2022)

Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Dutt, Tina, et al.
Publicado: (2020)

Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage
por: McDonnell, Thomas, et al.
Publicado: (2022)

Direct Oral FXa Inhibitors Binding to Human Serum Albumin: Spectroscopic, Calorimetric, and Computational Studies
por: Mariño-Ocampo, Nory, et al.
Publicado: (2023)

Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition
por: Han, Han, et al.
Publicado: (2021)

Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice
por: Pham, Phuong Tran, et al.
Publicado: (2019)

Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity
por: Amiral, Jean, et al.
Publicado: (2021)

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy
por: Demchuk, Andrew M., et al.
Publicado: (2021)

The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute the simple solution. Author's reply
por: Hofmaenner, Daniel A., et al.
Publicado: (2022)

Antiprothrombin antibodies induce platelet activation: A possible explanation for anti‐FXa therapy failure in patients with antiphospholipid syndrome?
por: Chayoua, Walid, et al.
Publicado: (2021)

Rivaroxaban Suppresses Atherosclerosis by Inhibiting FXa-Induced Macrophage M1 Polarization-Mediated Phenotypic Conversion of Vascular Smooth Muscle Cells
por: Ma, Yanpeng, et al.
Publicado: (2021)

Genetically proxied interleukin-6 receptor inhibition: opposing associations with COVID-19 and pneumonia
por: Larsson, Susanna C., et al.
Publicado: (2021)

Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations
por: Margetić, Sandra, et al.
Publicado: (2019)

A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter
por: Farkh, Carine, et al.
Publicado: (2021)

Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial
por: Bhagirath, Vinai C., et al.
Publicado: (2017)

Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study
por: Yuan, Shuai, et al.
Publicado: (2021)

Green by Design: Convergent Synthesis, Computational Analyses, and Activity Evaluation of New FXa Inhibitors Bearing Peptide Triazole Linking Units
por: Rodríguez, Diego F., et al.
Publicado: (2021)

Genetic evidence for vitamin D and cardiovascular disease: choice of variants is critical
por: Burgess, Stephen, et al.
Publicado: (2022)

FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B.1.1.7 variant
por: Dong, Wenjuan, et al.
Publicado: (2021)

Leverage of genetic variants proxying smoking intensity to explore the broad health consequences of smoking
por: Gill, Dipender
Publicado: (2020)

Dose–response relationship between genetically proxied average blood glucose levels and incident coronary heart disease in individuals without diabetes mellitus
por: Burgess, Stephen, et al.
Publicado: (2021)

Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation
por: Santana-Romo, Fabián, et al.
Publicado: (2020)

Genetically proxied lean mass and risk of Alzheimer’s disease: mendelian randomisation study
por: Daghlas, Iyas, et al.
Publicado: (2023)

Genetically Predicted Pulse Pressure and Risk of Abdominal Aortic Aneurysm: A Mendelian Randomization Analysis
por: Burgess, Stephen, et al.
Publicado: (2022)

A hydrophobic patch (PLVIVG; 1481–1486) in the B‐domain of factor V‐short is crucial for its synergistic TFPIα‐cofactor activity with protein S and for the formation of the FXa‐inhibitory complex comprising FV‐short, TFPIα, and protein S
por: Dahlbäck, Björn, et al.
Publicado: (2022)

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study
por: Fang, Si, et al.
Publicado: (2023)

Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk
por: Harlow, Charli E, et al.
Publicado: (2022)

Treatment of severe covid-19 with interleukin 6 receptor inhibition
por: Rajasundaram, Skanda, et al.
Publicado: (2022)

Genetically proxied impaired GIPR signaling and risk of 6 cancers
por: Rogers, Miranda, et al.
Publicado: (2023)

Genetically Predicted Neutrophil-to-Lymphocyte Ratio and Coronary Artery Disease: Evidence From Mendelian Randomization
por: Cupido, Arjen J., et al.
Publicado: (2022)

Genetic predisposition to allergic diseases is inversely associated with risk of COVID‐19
por: Larsson, Susanna C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b5sfcp7p10pouftnlglel0kofd